Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor
Annals of Pharmacotherapy · 2025-06 · 59 (6) · 570-576
DOI: 10.1177/10600280241279904 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 27.09.2024. Verfasst von Cameron Lanier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johnson City Medical Center, Ballad Health, Johnson City, TN, USA. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Cefepime, Anti-Bacterial Agents, Urinary Tract Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Objective
To describe and analyze the pharmacodynamic and pharmacokinetic properties and clinical evidence supporting the efficacy and use of cefepime-enmetazobactam (FEP-EMT). Data Sources: A literature search was conducted using MEDLINE and EMBASE databases (January 2015 to May 2024). Search terms included: “cefepime-enmetazobactam” or “cefepime” or “enmetazobactam” or “cefepime” or “novel beta-lactamase inhibitor” and “complicated urinary tract infection” or “cUTI.” Conference abstracts, bibliographies, clinical trials, and drug monographs were included for review. Study Selection and Data Extraction: Relevant studies in English and clinical trials conducted in humans were reviewed. Data Synthesis: In February 2024, the Food and Drug Administration (FDA) approved the combination beta-lactam/beta-lactamase inhibitor (BL/BLI) FEP-EMT for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis following the completion of the Phase III ALLIUM trial comparing it to piperacillin-tazobactam (TZP). The trial resulted in 79.1% of the FEP-EMT group versus 58.9% of the TZP group meeting the primary outcome of clinical cure and microbiological eradication (95% CI 21.2 [14.3 to 27.9]). Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents: This review describes the use of FEP-EMT for the treatment of cUTI and compares its use to other novel BL/BLI combinations including utility in drug-resistant infections.
Conclusions
FEP-EMT provides an antimicrobial option to reduce overuse of carbapenems for extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. However, unlike other novel BL/BLI combinations, its limited spectrum of antibacterial effect for more difficult-to-treat pathogens and cost may also impact its overall utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johnson City Medical Center, Ballad Health, Johnson City, TN, USA.
- College of Pharmacy, The University of Tennessee Health Science Center, Knoxville, TN, USA.
- Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA.
ORCID-Profile: Cameron Lanier
Zitieren
APA
Lanier, C., Melton, T., & Covert, K. (2025). Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor. Annals of Pharmacotherapy, 59(6), 570-576. https://doi.org/10.1177/10600280241279904
Vancouver
Lanier C, Melton T, Covert K. Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor. Annals of Pharmacotherapy. 2025;59(6):570-576. doi:10.1177/10600280241279904
BibTeX
@article{Lanier2025,
author = {Lanier, Cameron and Melton, Tyler and Covert, Kelly},
title = {Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor},
journal = {Annals of Pharmacotherapy},
year = {2025},
volume = {59},
number = {6},
pages = {570--576},
doi = {10.1177/10600280241279904}
}
EUVIMED